), has launched a direct-to-consumer advertising campaign reinforcing that anti-obesity medications should not be used outside of US Food and Drug Administration indications., which aired before this year's Oscars ceremony, starts by stating, "Some people have been using medicine never meant for them.".
Caroline M. Apovian, MD, codirector of the Center for Weight Management and Wellness at Brigham and Women's Hospital in Boston, Massachusetts, agreed. She told, "We need more campaigns like this one to make an impact — all of the companies in the obesity field should be creating campaigns like this and so should the government and hospital systems."on the use of its tirzepatide drugs that highlights the company's position against use of the drugs for cosmetic weight loss.
Additionally, it should further reinforce that "these medications are for people struggling with obesity/overweight; they're not meant for the general population." And it might help build "empathy for those struggling with obesity/overweight." Apovian noted, "Patients who have seen the ads cannot get into our center due to the fact that we have so many people trying to get in for an appointment — we are hiring more obesity medicine specialists to help us. But this campaign and others to come will make an impact."
"We will know it worked if the payors — and Medicare, as well — start covering these life-saving medications," she said. "Eventually, the shortages should abate as time goes on and the pharma companies figure out how to do it."-based drugs , does not have a similar campaign. However, Allison Schneider, the company's director of media relations and issues management, pointedApovian has participated on advisory boards for Altimmune, Inc., CinFina Pharma, Inc.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NewsfromScience - 🏆 515. / 51 Read more »
Source: nbcchicago - 🏆 545. / 51 Read more »
Source: NBCNewsHealth - 🏆 707. / 51 Read more »
Source: TODAYshow - 🏆 389. / 55 Read more »
Source: CNBC - 🏆 12. / 72 Read more »
Source: PageSix - 🏆 320. / 59 Read more »